Omeros

OMER · NASDAQ

$16.55+$0.20 (+1.22%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $16.35

OMER analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $37.40 (+126.0% upside)

Low: $22.22
Now: $16.55
High: $57.75

Upgrades and downgrades

The latest rating actions, newest first

OMER analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Oct 14, 2026	Maintains	Overweight	$22.00	25%
Cantor Fitzgerald	Sep 22, 2026	Upgrade	Neutral → Overweight	$22.00	25%
HC Wainwright & Co.	Jun 26, 2026	Maintains	Buy	$40.00 → $33.00	36%
HC Wainwright & Co.	Jun 10, 2026	Maintains	Buy	$40.00	36%
HC Wainwright & Co.	May 14, 2026	Maintains	Buy	$40.00	36%
D. Boral Capital	Apr 21, 2026	Maintains	Buy	$36.00	29%
D. Boral Capital	Jan 27, 2026	Maintains	Buy	$36.00	29%
HC Wainwright & Co.	Jan 8, 2026	Maintains	Buy	$20.00 → $40.00	36%
D. Boral Capital	Jan 8, 2026	Maintains	Buy	$36.00	29%
D. Boral Capital	Dec 24, 2025	Maintains	Buy	$36.00	29%

The case for and against

Updated Oct 14, 2026

Bull case

Omeros is viewed favorably because YARTEMLEA’s early U.S. launch has already shown real commercial traction, with $28.5M of 2Q sales, 74 unique ordering accounts by 2Q, and about 75% of orders coming from adults, suggesting broadening adoption in a larger market than pediatric-first launches. The company’s outlook improves further as the permanent J-code went live July 1 and NTAP begins October 1, both of which should reduce reimbursement friction and support a launch that is already working before those tailwinds fully arrive. The thesis is also supported by physician feedback implying more than 30% market share over time and peak sales around $400M, while the EU remains upside and the Novo Nordisk partnership adds non-dilutive milestone and royalty value.

Bear case

Omeros is viewed negatively because its near-term fate remains highly dependent on narsoplimab, while development, regulatory, and commercialization setbacks could materially impair value if approval or sales disappoint. The European CHMP negative opinion in June and the ongoing re-examination underscore regulatory risk, and the limited eligible TA-TMA population plus competition from larger, better-resourced companies further constrain the addressable market and execution outlook. Even with the U.S. YARTEMLEA launch and NVO partnership, the investment case is still vulnerable to pipeline and clinical trial uncertainty, with a 12.5% WACC and 12.0x exit multiple reflecting that risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.